KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables: 2009-2025

Historic Receivables for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $3.8 billion.

  • Teva Pharmaceutical Industries' Receivables rose 10.05% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 billion, marking a year-over-year decrease of 1.95%. This contributed to the annual value of $3.1 billion for FY2024, which is 10.24% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Receivables stood at $3.8 billion for Q3 2025, which was up 6.90% from $3.6 billion recorded in Q2 2025.
  • Teva Pharmaceutical Industries' Receivables' 5-year high stood at $4.6 billion during Q1 2021, with a 5-year trough of $3.1 billion in Q4 2024.
  • Moreover, its 3-year median value for Receivables was $3.5 billion (2024), whereas its average is $3.5 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Receivables declined by 20.85% in 2023 and then increased by 10.05% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Receivables (Quarterly) stood at $4.5 billion in 2021, then dropped by 18.39% to $3.7 billion in 2022, then fell by 7.79% to $3.4 billion in 2023, then declined by 10.24% to $3.1 billion in 2024, then increased by 10.05% to $3.8 billion in 2025.
  • Its Receivables was $3.8 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $3.4 billion in Q1 2025.